Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma

20260 citationsJournal Article

Authors

Hiroki Ishihara · Kawaguchi Junior College

Koichi Nishimura · Tokyo Women's Medical University Adachi Medical Center

Yuki Nemoto · Jyoban Hospital of Tokiwa Foundation

Shinsuke Mizoguchi · Saiseikai Ibaraki Hospital

Takayuki Nakayama · Tokyo Women's Medical University

Hironori Fukuda · Tokyo Women's Medical University

Hiroaki Shimmura

Abstract

Third-line systemic therapy following ICI combinations and sequential VEGFR-TKIs shows feasible clinical effectiveness and manageable toxicity in real-world patients with advanced RCC.

Topics & Keywords

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Japanese Journal of Clinical Oncology

DOI: 10.1093/jjco/hyag037

Field-Weighted Citation Impact: 0.00